NCT04025554View on ClinicalTrials.gov

Anakinra for the Treatment of Chronically Inflamed White Matter Lesions in Multiple Sclerosis

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

8

Participants

Timeline

Start Date

October 25, 2019

Primary Completion Date

October 24, 2023

Study Completion Date

October 24, 2023

Conditions
Multiple Sclerosis
Interventions
DRUG

Anakinra

100 mg daily weeks 1-4, 200 mg daily weeks 5-8, 300 mg daily weeks 9-12.

Trial Locations (1)

20892

National Institutes of Health Clinical Center, Bethesda

All Listed Sponsors
lead

National Institute of Neurological Disorders and Stroke (NINDS)

NIH

NCT04025554 - Anakinra for the Treatment of Chronically Inflamed White Matter Lesions in Multiple Sclerosis | Biotech Hunter | Biotech Hunter